These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35925809)

  • 1. High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study.
    Talal AH; Sofikitou EM; Wang K; Dickerson S; Jaanimägi U; Markatou M
    Telemed J E Health; 2023 Mar; 29(3):395-407. PubMed ID: 35925809
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C).
    Talal AH; Markatou M; Sofikitou EM; Brown LS; Perumalswami P; Dinani A; Tobin JN
    Contemp Clin Trials; 2022 Jan; 112():106632. PubMed ID: 34813962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers.
    Talal AH; Jaanimägi U; Davis K; Bailey J; Bauer BM; Dharia A; George S; McLeod A; Morton K; Nugent A; Zeremski M; Dinani A; Des Jarlais DC; Perumalswami PV; Tobin JN; Dickerson SS
    J Subst Abuse Treat; 2021 Aug; 127():108421. PubMed ID: 34134875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program.
    Talal AH; McLeod A; Andrews P; Nieves-McGrath H; Chen Y; Reynolds A; Sylvester C; Dickerson SS; Markatou M; Brown LS
    Telemed J E Health; 2019 Sep; 25(9):791-801. PubMed ID: 30325701
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.
    Sherbuk JE; Knick TK; Canan C; Ross P; Helbert B; Cantrell ES; Cantrell CJ; Stallings R; Barron N; Jordan D; McManus KA; Dillingham R
    J Infect Dis; 2020 Sep; 222(Suppl 5):S354-S364. PubMed ID: 32877562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone.
    Talal AH; Andrews P; Mcleod A; Chen Y; Sylvester C; Markatou M; Brown LS
    Clin Infect Dis; 2019 Jul; 69(2):323-331. PubMed ID: 30329042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient satisfaction with telemedicine in the Philippines during the COVID-19 pandemic: a mixed methods study.
    Noceda AVG; Acierto LMM; Bertiz MCC; Dionisio DEH; Laurito CBL; Sanchez GAT; Loreche AM
    BMC Health Serv Res; 2023 Mar; 23(1):277. PubMed ID: 36949479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study.
    Ochalek TA; Heil SH; Higgins ST; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2018 Sep; 190():224-228. PubMed ID: 30056321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.
    Spaderna M; Kattakuzhy S; Kang SJ; George N; Bijole P; Ebah E; Eyasu R; Ogbumbadiugha O; Silk R; Gannon C; Davis A; Cover A; Gayle B; Narayanan S; Pao M; Kottilil S; Rosenthal E
    Int J Drug Policy; 2023 Jan; 111():103906. PubMed ID: 36384062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status.
    Pro G; Tompkins DA; Azari S; Zaller N
    Drug Alcohol Depend; 2021 Nov; 228():109092. PubMed ID: 34571287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A framework for patient-centered telemedicine: Application and lessons learned from vulnerable populations.
    Talal AH; Sofikitou EM; Jaanimägi U; Zeremski M; Tobin JN; Markatou M
    J Biomed Inform; 2020 Dec; 112():103622. PubMed ID: 33186707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
    Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
    Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telemedicine, Patient Satisfaction, and Chronic Rhinosinusitis Care in the Era of COVID-19.
    Morisada MV; Hwang J; Gill AS; Wilson MD; Strong EB; Steele TO
    Am J Rhinol Allergy; 2021 Jul; 35(4):494-499. PubMed ID: 33115249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.
    Falade-Nwulia O; Irvin R; Merkow A; Sulkowski M; Niculescu A; Olsen Y; Stoller K; Thomas DL; Latkin C; Mehta SH
    J Subst Abuse Treat; 2019 May; 100():45-51. PubMed ID: 30898327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.
    Marchand KI; Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Schechter MT
    BMC Health Serv Res; 2011 Jul; 11():174. PubMed ID: 21791093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.